British American Tobacco Plc ADR (BTI) concluded trading on Thursday at a closing price of $52.62, with 4.56 million shares of worth about $239.77 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 43.89% during that period and on July 24, 2025 the price saw a gain of about 0.48%. Currently the company’s common shares owned by public are about 2.20B shares, out of which, 2.18B shares are available for trading.
Stock saw a price change of 2.51% in past 5 days and over the past one month there was a price change of 8.49%. Year-to-date (YTD), BTI shares are showing a performance of 56.98% which increased to 44.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $33.18 but also hit the highest price of $52.42 during that period. The average intraday trading volume for British American Tobacco Plc ADR shares is 6.67 million. The stock is currently trading 5.29% above its 20-day simple moving average (SMA20), while that difference is up 10.39% for SMA50 and it goes to 28.89% higher than SMA200.
British American Tobacco Plc ADR (NYSE: BTI) currently have 2.20B outstanding shares and institutions hold larger chunk of about 10.90% of that.
The stock has a current market capitalization of $115.05B and its 3Y-monthly beta is at 0.39. PE ratio of stock for trailing 12 months is 31.20, while it has posted earnings per share of $1.69 in the same period. Its PEG reads 6.75 and has Quick Ratio of 0.52 while making debt-to-equity ratio of 0.74. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BTI, volatility over the week remained 1.36% while standing at 1.51% over the month.
Stock’s fiscal year EPS is expected to rise by 1.90% while it is estimated to increase by 5.33% in next year. EPS is likely to grow at an annualized rate of 4.62% for next 5-years, compared to annual growth of -11.33% made by the stock over the past 5-years.
On January 27, 2025, UBS Upgrade their recommendations, while on October 03, 2024, Morgan Stanley Downgrade their ratings for the stock with a price target of $33. Stock get a Neutral rating from UBS on January 23, 2024.
